Market Signal Briefing

HomeEarnings AnalysisTech 

SummaryAdvanced Micro Devices, Inc. delivered a strong Q4, beating revenue and EPS consensus with robust Data Center and Client performance.AMD’s Q1 2026 guidance implies a sequential step-down, but part of that is simply China-related MI308 revenue normalizing, plus a more back-half-weighted demand profile.Long-term targets remain aggressive: 35% revenue CAGR, Data Center at ~60% CAGR, and a $100B revenue goal by 2030.The recent AMD share price decline appears exaggerated, presenting a potential entry point for investors seeking exposure to AMD's growth thesis. JHVEPhoto/iStock Editorial via Getty Images

I’ve become more optimistic on Advanced Micro Devices, Inc. (AMD), lately. For the first time in a while, the company is not just selling a GPU roadmap. It is laying out a real system

Analyst’s Disclosure: I/we have a beneficial long position in the shares of AMD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Key Takeaways Copa Holdings is expected to post Q4 EPS of $4.40, up 10.3% year over year, on revenues of $965.5M. CPA's Q4 revenue outlook is supported by stronger air-travel demand and higher capacity across its network. Cost pressures from wages and airport charges are expected to push operating costs up 12.1% in the quarter. Copa Holdings (CPA - Free Report)   is scheduled to report fourth-quarter 2025 results on Feb. 11, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings per share and revenues is pegged at $4.40 and $965.49 million, respectively.

The bottom-line projection indicates year-over-year growth of 10.3%. The consensus mark for the to-be-reported quarter’s earnings per share has been revised upward by 1 cent over the past 60 days. The Zacks Consensus Estimate for quarterly revenues implies a year-over-year expansion of 10.1%.

Image Source: Zacks Investment Research

For 2025, the Zacks Consensus Estimate for CPA’s revenues is pegged at $3.62 billion, implying a 5.1% year-over-year uptick. The consensus mark for 2025 EPS is pegged at $16.71, indicating year-over-year growth of approximately 14.8%.

In the trailing four quarters, this Latin American airline company’s earnings beat estimates on each occasion, with the average surprise being 8.2%.

Q4 Earnings Whispers for CPAOur proven model does not predict an earnings beat for CPA for the fourth quarter. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

CPA has an Earnings ESP of +1.06% and a Zacks Rank #4 (Sell).

Factors Likely to Have Influenced CPA’s Q4 PerformanceThe top line in the to-be-reported quarter is expected to have been bolstered by the improvement in air-travel demand.

In order to cater to this improvement, CPA has been boosting its capacity. For 2025, CPA expects consolidated capacity to grow 8% year over year, and the operating margin is expected to be in the range of 22-23%. The load factor for 2025 is expected to be 87% (higher than 86.3% reported in 2024).

Passenger revenues, which account for the bulk of the top line, are likely to have increased in the to-be-reported quarter. Our estimate for passenger revenues is pegged at $900.3 million, up 8.9% compared with the fourth-quarter 2024 actuals. Meanwhile, the consensus mark for revenues from the cargo and mail segment is pegged at $34.2 million, indicating an increase of 18.1% year over year.

On the contrary, CPA expects to continue experiencing increased cost pressure from wages, salaries, benefits and other employee expenses, airport facilities and handling charges. We expect operating costs to increase 12.1% in fourth-quarter 2025 from fourth-quarter 2024 actuals, led by the 10.5% rise in wages, salaries, benefits and other employee expenses, and 10.3% rise in airport facilities and handling charges.

Highlights of CPA’s Q3 EarningsCopa Holdings reported third-quarter 2025 earnings per share of $4.20, which surpassed the Zacks Consensus Estimate of $4.03 and improved 20% year over year. Revenues of $913.1 million missed the Zacks Consensus Estimate of $915 million but inched up 6.8% year over year.

Passenger revenues (which contributed 94.3% to the top line) grew 5.2% year over year to $861.33 million. The upside was owing to an 8% year-over-year increase in revenue passenger miles, partially offset by a 2.6% decrease in yield.

Stocks to ConsiderHere are a few stocks from the broader Zacks Transportation sector that investors may consider, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle. 

Expeditors International of Washington (EXPD - Free Report) has an Earnings ESP of +0.34% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

EXPD is scheduled to report fourth-quarter 2025 earnings on Feb. 24. The Zacks Consensus Estimate for fourth-quarter 2025 earnings has remained flat over the past 60 days. EXPD’s earnings beat the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 13.94%. 

Ryder System (R - Free Report) has an Earnings ESP of +0.27% and a Zacks Rank #3 at present. R is scheduled to report fourth-quarter 2025 earnings on Feb. 11.

The Zacks Consensus Estimate for fourth-quarter 2025 earnings has been revised upward by 0.27% over the past 60 days. Ryder’s earnings beat the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 2.6%.  

HomeIndustriesInternet/Online ServicesThe Ratings GameThe Ratings GameShares declined Thursday as Google’s staggering $185 billion capital-expenditure forecast overshadowed a blowout fourth quarterPublished: Feb. 5, 2026 at 11:41 a.m. ET

Even with monster cloud-revenue growth of 48%, Alphabet hasn’t earned the benefit of the doubt around its rapidly rising artificial-intelligence spending.

At least that’s what the stock’s 3% Thursday morning decline would suggest. While numerous analysts said Alphabet GOOG GOOGL is a rare example of how AI spending can drive a serious financial uplift, investors seem skittish about the fact that the Google parent’s capital expenditures could roughly double this year.

Most Popular

Key Takeaways Motorola reports Q4 on Feb.11, with consensus revenues of $3.34B, rising from the year-ago quarter.MSI gains near-term revenues from Silvus StreamCaster launches and U.S. DoD approval, enabling defense orders.Motorola boosts software and services via AI-assisted policing tools and the Blue Eye acquisition. Motorola Solutions, Inc. (MSI - Free Report) is scheduled to report fourth-quarter 2025 results on Feb.11, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 5.45%. It pulled off a trailing four-quarter earnings surprise of 5.5%, on average, beating estimates in all the previous occasions.

The Chicago, IL-based company is expected to have reported year-over-year revenue growth, driven by steady demand across its core businesses, disciplined cost management, and diligent execution of operational plans.

Factors at PlayDuring the to-be-reported quarter, the launch of Silvus’ StreamCaster NEXUS strengthened Motorola’s tactical networking portfolio and is likely to have supported near-term revenues through early customer adoption, pilot deployments, and initial defense orders. 

During the fourth quarter, Motorola’s advancement of AI-assisted policing tools is likely to have supported near-term revenues by driving higher adoption of software subscriptions and upgrades from public safety agencies. Increased demand for AI-driven dispatch, reporting, and response solutions might have boosted the company’s bookings and recurring software revenues in the quarter.

The acquisition of Blue Eye adds AI-powered remote video monitoring services to its portfolio. Early cross-sell opportunities, subscription integrations, and new customer contracts can drive immediate bookings and recurring service revenues, supporting its software and services growth in the quarter. 

During the quarter, the U.S. Department of Defense's approval of the Silvus StreamCaster 4400 Enhanced MANET radio as a secure and reliable communication tool strengthens Motorola’s defense portfolio and supports near-term revenues by enabling participation in secure U.S. military drone programs. This certification might have driven early orders and contract activity from defense customers, generating revenues in the current quarter.

Riding on a strong product portfolio, ongoing investment in innovation and efficiency should have helped Motorola maintain healthy margins, supported by a strong order pipeline and improving market conditions.

Overall ExpectationsThe Zacks Consensus Estimate for the Products and Systems Integration segment’s revenues is pegged at $2.13 billion. The figure indicates a rise from $1.95 billion recorded in the year-ago quarter. The Zacks Consensus Estimate for the Services and Software segment’s revenues is pegged at $1.21 billion compared with $1.06 billion recorded in the year-earlier quarter. 

For the December quarter, the Zacks Consensus Estimate for revenues is pegged at $3.34 billion, which indicates growth from the year-ago quarter’s reported figure of $3.01 billion. The consensus estimate for adjusted earnings per share is $4.36, up from $4.04, driven by top-line growth.

Earnings WhispersOur proven model does not predict an earnings beat for Motorola for the fourth quarter. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here.

Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% with both pegged at $4.36 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: Motorola carries a Zacks Rank #2 at present. 

Motorola Solutions, Inc. Price and EPS Surprise

Motorola Solutions, Inc. price-eps-surprise | Motorola Solutions, Inc. Quote

Stocks to ConsiderHere are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season:

Akamai Technologies, Inc. (AKAM - Free Report) is set to release its fourth-quarter 2025 numbers on Feb. 19. It has an Earnings ESP of +1.97% and carries a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Earnings ESP for IPG Photonics Corporation (IPGP - Free Report) is +15.08%, and it sports a Zacks Rank of 1 at present. The company is scheduled to report fourth-quarter 2025 numbers on Feb. 12.

The Earnings ESP for Applied Materials, Inc. (AMAT - Free Report) is +2.99%, and it carries a Zacks Rank of 2 at present. The company is scheduled to report first-quarter fiscal 2026 numbers on Feb. 12.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Peloton Interactive (NASDAQ:PTON) surged during the pandemic as home fitness demand exploded, with revenue peaking at $4.1 billion in fiscal 2021. Since then, it has steadily declined, shedding market value and users. Sales have fallen amid economic pressures, while membership rolls have shrunk as consumers return to gyms or cut spending. Product updates, such as redesigned bikes and treads, have failed to capture broad interest in a price-sensitive market. 

Following its fiscal second-quarter 2026 earnings release yesterday, Peloton reported further revenue shortfalls and subscriber losses, appearing as a weakened entity struggling to regain footing and potentially facing ongoing erosion. Is the connected fitness guru just a dead stock walking?

Earnings Reveal Ongoing Declines Peloton’s Q2 results showed total revenue of $657 million, a 3% decrease from $674 million in the same quarter a year earlier. This figure fell $8 million short of the company’s own guidance and missed analyst expectations of $674 million. The decline stemmed mainly from weaker equipment sales to existing customers and some delivery delays that pushed $4 million in revenue into the next quarter.

Connected Fitness Products revenue, which includes hardware like bikes and treads, totaled $244 million, down 4% year-over-year. Subscription revenue reached $413 million, a 2% drop from the prior year, affected by fewer paid subscribers and reduced content licensing income, though partially offset by price increases.

The company posted a net loss of $39 million, or $0.09 per share, an improvement from the $92 million loss, or $0.24 per share, in the year-ago period, but worse than the expected $0.06 loss. Adjusted EBITDA, however, rose 39% to $81 million, exceeding guidance by $6 million, reflecting cost controls.

Membership levels, though, continued to erode at a worrisome pace. Ending paid Connected Fitness subscriptions stood at 2.661 million, a 7% decline from 2.875 million a year prior, though 6,000 above the guidance midpoint. Total members numbered 5.8 million, down 6% year-over-year. Average monthly churn for paid Connected Fitness subscriptions was 1.9%, up 50 basis points from last year, but better than anticipated after an October price hike.

New Products Fail to Spark a Revival Management highlighted the October launch of the Peloton Cross Training Series, which refreshed the entire hardware lineup with features like swivel screens, improved saddles, and AI-driven coaching via Peloton IQ. The series includes the Cross Training Bike, Bike+, Tread, Tread+, and Row+, aimed at cross-training users. It received positive reviews from media outlets, but the products have not driven expected sales. 

Equipment sales to existing members were lower than anticipated, extending upgrade cycles due to the durability of older hardware and high satisfaction among owners. Sales to new customers met projections, with over 70% of cross-training sales to bike owners being treads or rows. Third-party retail performance also lagged, contributing to the revenue miss.

The 4% drop in product revenue likely reflects Peloton’s premium pricing — bikes start at $1,495, treadmills at $2,995 — in an environment where consumers prioritize budgets amid inflation and competing fitness options. This pressure also hit subscriptions, with the 7% decline tied to fewer hardware activations and higher churn after the price increase.

Adding to its challenges, CFO Liz Coddington announced her departure effective in March to join a private clean tech energy company.

Key Takeaway Despite some earlier Wall Street optimism — one analyst projected  a 236% stock gain and consensus targets implying 70% upside — Peloton’s trajectory suggests continuing declines. Analysts have issued mixed ratings, but recent results undercut turnaround hopes. The stock plummeted 23% this morning, contributing to a 25% year-to-date drop from $6.12 at the start of the year, and is down 36% of the last 12 months, erasing gains from an early 2025 rally as the broader market recovered.

Peloton holds $1.18 billion in cash and equivalents, but faces $1.499 billion in total debt, including a $946 million term loan and $344 million in convertible notes. It also has $381 million in operating leasing liabilities. With guidance forecasting a 3% full-year revenue decline to $2.40 billion to $2.44 billion and an 8% drop in Q3 subscriptions, the connected fitness guru appears to be living on borrowed time.

If You have $500,000 Saved, Retirement Could Be Closer Than You Think (sponsor) Retirement can be daunting, but it doesn’t need to be. Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter! Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality. (sponsor)

Elf Beauty Inc (NYSE:ELF) shares fell more than 5% on Thursday after the company reported third quarter fiscal 2026 results and raised its full-year guidance, with the increase seen as modest relative to analyst expectations.

For the three months ended December 31, 2025, Elf Beauty posted net sales of $489.5 million, surpassing Wall Street’s consensus estimate of roughly $460 million.

Adjusted earnings per share came in at $1.24, above the expected $0.72.

“Our Q3 results, which included 130 basis points of market share gains for our namesake e.l.f. Cosmetics brand and a record-breaking launch of rhode in Sephora in the UK, are a continuation of the consistent, category-leading growth we’ve delivered over the past 28 quarters,” Elf CEO Tarang Amin said in a statement.

“We remain confident in our ability to grow market share and deliver best-in-class growth in beauty, as reflected by our raised fiscal 2026 outlook.”

Despite the top-line and EPS beats, shares declined after Elf raised its full-year net sales growth outlook to 22% to 23%, implying roughly $2.55 billion to $2.58 billion in total sales. The midpoint of the range, around $2.565 billion, remained below analysts’ pre-earnings consensus of approximately $2.6 billion.

Much of the guidance increase was driven by Rhode, the company’s recently acquired brand, which is now expected to contribute $260 million to 265 million for the full year, up from a prior forecast of $200 million.

Jefferies highlighted that while Q3 results exceeded expectations across sales, EBITDA, and EPS, investor focus remains on Elf’s core business performance.

The firm noted Rhode’s outsized contribution but emphasized that organic growth of roughly 2% in the second half reflects softer global consumption and a 4-point pipeline headwind. “While Rhode’s strength is notable, sentiment remains centered on core business visibility,” Jefferies wrote.

The firm also pointed out that Elf’s guidance appears conservative relative to strong US scanner data and ongoing category outperformance, suggesting potential upside from marketing initiatives, geographic expansion, and pipeline normalization.

The firm maintained a price target of $115.

Konecranes Plc (KNCRY) Q4 2025 Earnings Call February 5, 2026 7:00 AM EST

Company Participants

Linda Hakkila - Chief Investor Relations Officer
Marko Tulokas - President & CEO
Teo Ottola - CFO & Deputy CEO

Conference Call Participants

Daniela Costa - Goldman Sachs Group, Inc., Research Division
Antti Kansanen - SEB, Research Division
Mikael Doepel - Nordea Markets, Research Division

Presentation

Linda Hakkila
Chief Investor Relations Officer

Hello all, and welcome to follow Konecranes' Q4 2025 Results Webcast.

My name is Linda Hakkila, I'm the VP, Investor Relations here at Konecranes. And with me today, as our main speakers, we have our CEO, Marko Tulokas; and our CFO, Teo Ottola.

Before we proceed, I would like to remind you about the disclaimer as we might be making forward-looking statements.

As per usual, we will first start with presentations, both from our CEO and CFO. And after that, we will start the Q&A session. We are happy to answer your questions through the conference call lines. But now without any further comments, I would like to hand over to our CEO.

Marko Tulokas
President & CEO

Thank you, Linda, and good afternoon from cold, but very sunny Helsinki. I'd like to start with some general statements.

It was a really very strong year for Konecranes, and I'm very, very proud of our team and very proud to be part of the Konecranes team, particularly in a year like 2025. Konecranes has a very sound business model. We've been executing our strategy. And that, of course, in this sort of environment has really improved -- shown that an improved resilience in our results.

There was a very uncertain environment last year. We focused on executing our strategy and focused on the most important things. The year started on uncertain terms, but we acted fast and early, whether it's on

Q4: 2026-02-04 Earnings SummaryEPS of $2.49 beats by $0.15

 |

Revenue of

$24.19B

(22.56% Y/Y)

misses by $7.44B

MetLife, Inc. (MET) Q4 2025 Earnings Call February 5, 2026 9:00 AM EST

Company Participants

John Hall - Senior VP, Head of Investor Relations & Executive VP and Treasurer
Michel Khalaf - CEO, President & Director
John McCallion - Executive VP, CFO & Head of Investment Management
Ramy Tadros - Regional President of U.S. Business & Head of MetLife Holdings
Lyndon Oliver - Regional President of Asia

Conference Call Participants

Jamminder Bhullar - JPMorgan Chase & Co, Research Division
Thomas Gallagher - Evercore ISI Institutional Equities, Research Division
Joel Hurwitz - Dowling & Partners Securities, LLC
Suneet Kamath - Jefferies LLC, Research Division
Wesley Carmichael - Wells Fargo Securities, LLC, Research Division
Taylor Scott - Barclays Bank PLC, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the MetLife Fourth Quarter and Full Year 2025 Earnings and Outlook Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. Before we get started, I refer you to the cautionary note about forward-looking statements in yesterday's earnings release and to risk factors discussed in MetLife's SEC filings.

With that, I will turn the call over to John Hall, Global Head of Investor Relations. Please go ahead.

John Hall
Senior VP, Head of Investor Relations & Executive VP and Treasurer

Thank you, operator, and good morning, everyone. We appreciate you joining us for MetLife fourth quarter 2025 earnings and near-term outlook call. Before we begin, I'd point you to the information on non-GAAP measures on the Investor Relations portion of metlife.com, in our earnings release and in our quarterly financial supplements, which you should review.

On the call this morning are Michel Khalaf, President and Chief Executive Officer; and John McCallion, Chief Financial Officer and Head of MetLife Investment Management. Also available to participate in the discussion are other members of senior management. Last night, we released an earnings

Key Takeaways BDX heads into fiscal Q1 with the consensus estimate calling for $5.15 billion in revenues and $2.82 in EPS.BD's Medical segment is supported by biologics and GLP-1 demand plus adoption of new platforms.BD's Life Sciences gains from new assays and approvals, but the Chinese market and funding pressures remain. Becton Dickinson and Company (BDX - Free Report) , popularly known as BD, is scheduled to report first-quarter fiscal 2026 results on Feb. 9, before market open.

In the last reported quarter, the company’s adjusted earnings per share (EPS) of $3.96 surpassed the Zacks Consensus Estimate by 1%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 6.5%, on average.

Let’s check out the factors that have shaped BDX’s performance prior to this announcement.

Factors to Note Before BDX ReportsBD MedicalBD Medical’s strong fourth-quarter fiscal 2025 performance is expected to carry into the first quarter of fiscal 2026 as key growth drivers remain intact. In the fiscal fourth quarter, strength in Vascular Access Management and Infusion Systems in Medication Delivery Solutions and Medication Management Solutions business units, respectively, strong biologics demand in Pharmaceutical Systems (PS) unit and robust momentum in the Advanced Patient Monitoring unit, fueled by the HemoSphere Alta Monitor and Smart Recovery, all contributed to segment strength. This is likely to have continued in the to-be-reported quarter, supported by sustained demand for biologics and GLP-1 therapies. The segment is also likely to have benefited from the continued adoption of products, like Acumen IQ sensors.

During the quarter, the company launched BD Incada Connected Care Platform, a new scalable, AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem. It is now available with the next-generation BD Pyxis Pro Automated Medication Dispensing Solution, creating enterprise-wide visibility and connectivity that transforms data into actionable insight. This is likely to have witnessed strong customer adoption, thereby driving up the segmental revenues.

The Zacks Consensus Estimate for the first quarter of fiscal 2026 BD Medical segment’s revenues is currently pegged at $2.59 billion.

BD Life SciencesIn December 2025, BD announced the expansion of its respiratory and sexually transmitted infection diagnostics offerings in Europe following In Vitro Diagnostic Medical Device Regulation certification of two VIASURE assays developed by Certest Biotec for use on the BD MAX System. The addition of these new assays to the BD MAX System portfolio is expected to enable clinical laboratories to detect a broad range of pathogens quickly and accurately using a fully automated molecular platform.

The same month, BD announced the global commercial release of new configurations of cell analyzers featuring breakthrough spectral and real-time cell imaging technologies. The three- and four-laser BD FACSDiscover A8 Cell Analyzers will likely expand accessibility of spectral, real-time imaging cell analysis.

In October, the segment’s Diagnostic Solutions (DS) business unit announced a new self-collection solution for HPV (human papillomavirus) testing in markets outside the United States, broadening access to cervical cancer screening. These are likely to have witnessed encouraging product adoption during the to-be-reported quarter, thereby driving the segmental revenues.

In November, BD announced that the Conformité Européenne (CE) Marked BD Onclarity HPV Assay for the BD COR System and the BD Viper LT System have been accepted for the World Health Organization list of prequalified in vitro diagnostic products. This is expected to expand access to high-quality cervical cancer screening tools in low- and middle-income countries. The same month, BD received the FDA’s 510(k) clearance and CE marking in the European Union for its Enteric Bacterial Panel (EBP) and Enteric Bacterial Panel plus (EBP plus) for the BD COR System. These also look promising for the stock.

However, BD continued to face market dynamics in China, which impacted its Specimen Management business unit’s performance in fourth-quarter fiscal 2025. The company’s research funding was also impacted by continued market dynamics during the fiscal fourth quarter. These raise our apprehension about the company’s performance in the to-be-reported quarter.

The Zacks Consensus Estimate for first-quarter fiscal 2026 BD Life Sciences revenues is currently pegged at $1.32 billion, suggesting an uptick of 1.9% from the year-ago quarter’s reported figure.

BD InterventionalIn November, the company launched the BD Surgiphor Surgical Wound Irrigation System in Europe, which is the first of its kind to receive CE approval. It is now available in select European countries. The same month, BD introduced the PureWick Portable Collection System, a discreet, battery-powered personal urine management device designed for wheelchair users to help improve mobility around and outside the home. These products are expected to have witnessed robust customer adoption during the fiscal first quarter, thereby driving up the segmental revenues.

On fourth-quarter fiscal 2025 earnings call in November, management stated that the company’s organic growth was led by robust growth in BD Interventional with strong performance across its growth platforms. This includes strong sales in the Urology & Critical Care business unit, driven by PureWick and in Surgery business unit, led by the Advanced Tissue Regeneration platform, including continued strong adoption of Phasix resorbable mesh. Growth in the Peripheral Intervention business unit reflected strength across the oncology portfolio and Rotarex. We expect this momentum to have continued in the first quarter of fiscal 2026.

The Zacks Consensus Estimate for first-quarter fiscal 2026 BD Interventional revenues is currently pegged at $1.30 billion, suggesting an uptick of 3.6% from the year-ago quarter’s reported figure.

BD’s Estimate PictureFor first-quarter fiscal 2026, the Zacks Consensus Estimate for revenues is pegged at $5.15 billion, implying a decline of 0.4% from the prior-year quarter’s reported figure.

The consensus estimate for EPS is pegged at $2.82, indicating a decrease of 17.8% from the prior-year period’s reported number.

What Our Model Suggests About BDXPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.

Earnings ESP: BD has an Earnings ESP of -0.56%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.

BD’s Share Price PerformanceOver the past three months, BD’s shares have gained 17.2%, outperforming the Medical - Dental Supplies’ 2.7% gain. BDX’s shares also outperformed the Zacks Medical sector’s increase of 8.5% and the S&P 500’s growth of 3.3%.

Three Months Price Comparison
Image Source: Zacks Investment Research

BD’s peer, Globus Medical, Inc. (GMED - Free Report) , has outperformed the company, while other peers like Masimo Corporation (MASI - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) have underperformed. GMED, MASI and MMSI’s shares are up 41.1%, down 5% and down 8.3%, respectively, in the same time frame.

BDX’s Key Valuation MetricFrom a valuation standpoint, BDX’s forward 12-month price-to-earnings (P/E) is 13.7X, a discount to the industry's average of 17.5X and its five-year median of 18.5X.

Image Source: Zacks Investment Research

The company is trading at a discount to its peers, Globus Medical, Masimo and Merit Medical. Globus Medical, Masimo and Merit Medical’s P/E currently stand at 21.9X, 23.5X and 19.5X, respectively.

This suggests that investors may be paying a lower price relative to the company's expected sales growth.

BD’s Long-Term Investment VisibilityLast month, BD and Envetec Sustainable Technologies announced the successful completion of a joint feasibility study to test the ability to recycle polystyrene Petri dishes into new, high-quality manufacturing feedstock. The results of the pilot study suggest that similar high-quality polymers, including polystyrene, polyester, polypropylene and polyethylene, could be reused in the manufacturing supply chain after being safely disinfected and processed. These polymers find extensive use in medical devices, such as those made by BD.

The same month, BD announced that the company's board of directors had set the close of business on Feb. 5, 2026, as the record date for the previously announced spin-off of BD's Biosciences (BDB) & DS business units. Immediately following the spin-off, the spun-off entity will be combined with Waters Corporation. BD had announced the definitive agreement to combine its BDB & DS business with Waters in July 2025. Per BD’s management, the agreement will likely bring together complementary portfolios and channels that create an industry-leading life science and diagnostics company. This looks promising for BD as it is expected to enhance its strategic focus as a medical technology company.

Also, in January, BD and Ypsomed announced that they are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak XtraFlow Glass Prefillable Syringe. The same month, BD announced an $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the United States. This investment will bring BD Neopak Glass Prefillable Syringe production to Columbus, NE, thus reinforcing its supply resilience within its PS portfolio.

In January, BD announced that the FDA granted 510(k) clearance for the EnCor EnCompass Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy system designed to provide clinicians with flexibility across breast imaging modalities in the diagnosis of breast disease. This looks promising for the company.

In December, BD announced a strategic collaboration with the Institute for Immunology and Immune Health at the University of Pennsylvania to advance research in deep human immune profiling and support the development of immune-mediated therapies. The same month, BDX announced a strategic collaboration with ChemoGLO to advance hazardous drug contamination testing in health care settings to improve the safety of health care workers. These partnerships raise our optimism about the stock’s performance in the long term.

However, BD’s strong performance in the fiscal fourth quarter was partially offset by continued market dynamics in China, which is likely to have continued in the to-be-reported quarter. The current unstable macroeconomic business environment is also likely to have weighed on the company’s fiscal first-quarter revenues, raising our apprehension.

Key Takeaways LIN posted Q4 adjusted EPS of $4.20, beating estimates, as revenues rose year over year to $8.76 billion.Linde's Americas profit rose 4.5% to $1.2B, driven by higher pricing and volumes, mainly in electronics.LIN ended Q425 with a $10 billion project backlog and guided 2026 adjusted EPS to $17.40- $17.90. Linde plc (LIN - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $4.20, which surpassed the Zacks Consensus Estimate of $4.18. The bottom line also improved from the year-ago quarter’s figure of $3.97.

Total quarterly revenues of $8,764 million surpassed the Zacks Consensus Estimate of $8,561 million. The top line also increased from the year-ago quarter’s level of $8,282 million.

The strong quarterly results can be attributed to higher pricing and increased volumes from the Americas segment.

LIN’s Segmental HighlightsThe operating profit of Linde’s Americas segment increased 4.5% to $1,202 million from $1,150 million in the prior-year quarter. The Zacks Consensus Estimate for the same was pinned at $1,214 million. The segment was supported by higher pricing and increased volumes, primarily in the electronics end market.

Linde’s profit in the EMEA segment increased approximately 12.5% year over year to $772 million. Additionally, profit from this segment beat the Zacks Consensus Estimate of $739 million. The segment was aided by higher pricing, partially offset by lower volumes, primarily in the chemicals & energy end market.

The APAC segment's profit increased from $500 million a year ago to $502 million. The Zacks Consensus Estimate for the same was pegged at $497 million. The increase was driven by higher volumes, mainly in the electronics and chemicals & energy end markets.

Operating profit in the Engineering segment declined to $103 million from $106 million in the prior-year quarter. The reported figure surpassed the Zacks Consensus Estimate of $100 million.

LIN’s BacklogsAt the end of the fourth quarter, the company’s high-quality project backlog amounted to $10 billion, comprising a sale-of-gas backlog of $7.3 billion.

Linde’s Capital Investment & Balance SheetLinde reported capital expenditures of $1.46 billion for the fourth quarter. It ended the quarter with cash and cash equivalents of $5.1 billion and long-term debt of $20.7 billion.

LIN’s 2026 GuidanceFor 2026, Linde estimates adjusted EPS to lie in the range of $17.40- $17.90. For the first quarter of 2026, it expects adjusted EPS to be in the range of $4.20- $4.30. The company announced its full-year capital expenditure guidance to be in the range of $5-$5.5 billion.

LIN’s Zacks Rank & Other Key PicksLIN currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Some other stocks from the basic materials sector that are yet to report earnings are Coeur Mining, Inc. (CDE - Free Report) , Kinross Gold Corporation (KGC - Free Report) and Newmont Corporation (NEM - Free Report) .

Coeur Mining, Inc. primarily produces gold and silver and owns precious metal mines across the United States, Canada and Mexico. CDE is scheduled to release fourth-quarter 2025 earnings on Feb. 18. The Zacks Consensus Estimate for earnings is pegged at 42 cents per share, which implies an increase of 281.2% from the prior-year reported figure. The company sports a Zacks Rank #1.

Kinross Gold Corporation is one of the top 10 gold mining companies in the world. The company is focused on the acquisition, exploration and development of gold mines primarily located in the United States, Brazil, Chile, Canada and Mauritania. Kinross is scheduled to release fourth-quarter 2025 earnings on Feb. 18. The Zacks Consensus Estimate for KGC’s earnings is pegged at 55 cents per share, indicating a 175% increase from the prior-year reported figure. The company currently carries a Zacks Rank #3 (Hold). 

Newmont Corporation is one of the largest producers of gold globally and operates several mines in Nevada, Peru, Australia and Ghana. NEM is scheduled to release fourth-quarter 2025 earnings on Feb. 19. The Zacks Consensus Estimate for earnings is pegged at $1.78 per share, which implies an increase of 27.1% from the prior-year reported figure. The company carries a Zacks Rank #3.

Key Takeaways ISRG delivered 20.5% revenue growth in 2025, with high-teens Q4 sales and procedures up 18% year over year.ISRG's growth was fueled by procedure volumes, rising utilization and da Vinci 5 placements.ISRG sees 13-15% procedure growth in 2026, aided by FDA clearance for cardiac uses of da Vinci 5. Intuitive Surgical (ISRG - Free Report) delivered robust 2025 results, beating estimates on both counts. Total revenues rose 20.5% year over year to $10.1 billion. The company recorded adjusted earnings per share of $8.93, up 21.7%. The growth was driven by higher procedure volumes, supported by an expanding installed base and increased utilization. The company’s robotic-surgery systems were used to treat more than 3.1 million patients in 2025, marking an 18% year-over-year increase, while utilization across da Vinci platforms rose 3% globally.

The Instruments and accessories segment posted 18.5% sales growth during the year. Continued momentum in procedure volumes was supported by strong adoption of the flagship da Vinci 5 robotic system and its expansion into new surgical indications.

Intuitive Surgical plans to focus on the global expansion of its robotic platforms in 2026, particularly da Vinci 5, alongside increased investments in training, commercial execution and market access. da Vinci 5 received FDA clearance last month for use in certain cardiac procedures, including mitral valve repair and internal mammary artery mobilization for cardiac revascularization. ISRG estimates that this approval expands the total addressable market by approximately 160,000 procedures annually.

The company plans to introduce additional products and features in 2026 to enhance da Vinci 5 capabilities, potentially driving further procedure growth. In Japan, potential reimbursement for additional robotic procedures by mid-2026 could support a recovery in procedure volumes.

For 2026, Intuitive Surgical expects worldwide procedures to grow approximately 13-15%. While this guidance is lower than 2025 growth, the company had previously raised its outlook after procedure growth in 2025 exceeded initial expectations.

Peer UpdateStryker’s (SYK - Free Report) 2026 top-line outlook is increasingly anchored by MAKO. Management expects organic revenue growth of roughly 8-9.5% in 2026, with MAKO system placements and rising utilization acting as a durable growth flywheel.

With more than 3,000 systems installed globally, MAKO is driving downstream implant pull-through, particularly in knees and hips, where robotic penetration continues to climb. Shoulder and spine applications should expand MAKO’s addressable market. For Stryker, MAKO is no longer just a capital sale; it is a recurring revenue engine supporting procedure growth and reinforcing SYK’s ability to outgrow core orthopedics in 2026.

Zimmer Biomet’s (ZBH - Free Report) 2026 top-line trajectory is increasingly tied to execution around ROSA, its flagship robotic platform. Management has framed 2026 as a year of disciplined acceleration, with ROSA supporting procedure growth across knees, hips and shoulders. As ROSA adoption expands across CT-based, imageless, and shoulder applications, Zimmer Biomet expects robotics to enhance mix, improve surgeon efficiency, and strengthen competitiveness in both hospitals and ASCs.

ISRG’s Price Performance, Valuation and EstimatesShares of ISRG have risen 0.9% over the past six months compared with 2.8% growth for the industry.

Image Source: Zacks Investment Research

From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 47, above the industry average. But, it is still lower than its five-year median of 71.33. ISRG carries a Value Score of F.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 12.1% rise from the year-ago period’s level.

Image Source: Zacks Investment Research

The stock currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

New at-the-meter solution gives customers a lower-cost path to adopting EVs and electric appliances—without the delays and expense of traditional panel upgrades

, /PRNewswire/ -- Pacific Gas and Electric Company (PG&E) today announced a strategic collaboration with SPAN to deploy the company's SPAN Edge solution to help customers electrify their homes more affordably and efficiently.

SPAN Edge is an at-the-meter device that enables real-time load management and allows homes to add new electric appliances or electric vehicle charging without costly electric panel or service upgrades—addressing one of the most significant barriers to residential electrification.

SPAN Edge — an at the meter device enabling affordable, accelerated home electrification — shown connected directly to the meter as part of SPAN’s expanding collaboration with PG&E to help customers adopt electric technologies without costly panel upgrades. PG&E will deploy the new SPAN Edge devices coupled with next-generation metering infrastructure through its new PanelBoost program, a grid-edge innovation initiative designed to reduce upgrade costs for customers adopting electric vehicles, heat pumps, induction cooking, and other high efficiency electric technologies.

PG&E estimates that more than 600,000 homes in PG&E's service area are likely to require some type of electric service upgrade in the next decade to meet electrification demand.

"PG&E is committed to helping our customers electrify affordably while maintaining a reliable, resilient grid," said Mike Delaney, Vice President of Strategy & Innovation, PG&E. "Our work with SPAN aims to enable thousands of households to add electric appliances and EVs faster and without more costly panel and electric system upgrades."

PG&E joins a growing list of energy companies and grid partners, including Landis+Gyr, utilizing SPAN Edge to enable affordable customer electrification, manage distribution system upgrades and support the clean energy transition.

"Our partnership with PG&E is a critical step in making home electrification affordable and accessible," said Arch Rao, CEO of SPAN. "By deploying SPAN Edge at scale, we are helping PG&E customers bypass the traditional 'panel bottleneck' and accelerate the transition to clean energy."

A Scalable Solution for California's Load Growth
SPAN Edge uses a Dynamic Service Rating™ capability to shape home energy demand during peak events, helping protect local electric transformers and maintain grid reliability. This technology complements PG&E's broader grid edge, R&D, and innovation strategy to develop and deploy scalable smart-panel and meter-socket-based solutions to avoid expensive service upgrades for customers.

Electricians and installers participating in early PanelBoost feedback sessions praised the program for helping customers avoid electric panel service upgrades.

"PG&E just made it possible to effectively have a 200-amp panel by throttling the loads in their house," one installer noted. Customer testers echoed this sentiment, with several indicating they would have used this pathway before pursuing traditional upgrade work.

Building on the Success of PG&E's SAVE Program
SPAN Edge deployments will build on lessons learned from PG&E's successful Seasonal Aggregation of Versatile Energy (SAVE) virtual power plant program, which demonstrated the value of aggregating residential distributed energy resources to mitigate local grid constraints.

SPAN's existing customer-sited infrastructure and Dynamic Service Rating™ provided PG&E with valuable load-shaping capability and analytics—and future VPPs can further scale these benefits through at-the-meter technologies like SPAN Edge.

With California's energy demand expected to grow meaningfully due to transportation and building electrification, PanelBoost is designed to align with California Energy Commission forecasts and enable cost-effective customer transitions.

The program is a part of PG&E's broader innovation implementation strategy that incorporates extensive customer research, market analysis, and lessons learned from previous technology demonstrations.

Meaningful Economic and Grid Benefits
SPAN Edge devices are installed quickly at the electric meter. They offer utilities a reliable, flexible load-shaping tool and give customers a lower-cost path to electrification—avoiding service upgrades that can cost $6,000 to $40,000 and take months to complete. In comparison, the cost estimate for a customer to have an electrician to install a SPAN Edge device through PanelBoost could be between $500-$2,000 dependent on a range of factors.

Through PanelBoost, PG&E will supply the SPAN Edge device for customers as an add on to their electric meter, and customers will be responsible for the costs for an electrician to install the device and for costs to wire any new appliances and loads connecting to the device.

PG&E plans to launch a website with more information about the SPAN Edge PanelBoost offering in summer 2026.

PG&E plans to initially scale SPAN Edge devices to thousands of customers when the program kicks off later this summer, with further scale as the program develops over the next several years.

To learn more about PG&E's electrification programs and customer offerings, visit www.pge.com/electrification

About PG&E
Pacific Gas and Electric Company, a subsidiary of PG&E Corporation (NYSE: PCG), is a combined natural gas and electric utility serving more than sixteen million people across 70,000 square miles in Northern and Central California. For more information, visit pge.com, pge.com/news and pge.com/innovation.

About SPAN
SPAN is on a mission to enable electrification for all and provide energy management for every home. The company designs products that remove barriers to electrification, providing a holistic approach to managing increasing demands on household energy. Powering your home with clean energy should be a simple and delightful experience that is technology-forward and human-centered. For more information, go to www.span.io.

SOURCE Pacific Gas and Electric Company

February 05, 2026 11:50 ET  | Source: Angle Advisors LLC

Birmingham, MI, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Angle Advisors is pleased to announce that Thermo-Tech Mechanical Insulation, Inc. a leading provider of mechanical insulation services, has been acquired by Installed Building Products, Inc. (“IBP”). Angle Advisors acted as the exclusive investment banking advisor to Thermo-Tech in completing the transaction.

Installed Building Products acquired Thermo-Tech Mechanical Insulation

“Angle Advisors played a critical role in the successful sale of Thermo-Tech, bringing both industry insight and rigorous transaction execution. Their team managed a complex process with professionalism and focus, resulting in a successful outcome for Thermo-Tech,” said David Schroeder, President, Thermo-Tech.

Headquartered in Watertown, Wisconsin, Themo-Tech (“Thermo-Tech” or the “Company”) has a 40-year history in insulation contracting offering state-of-the-art mechanical insulation products and installation services.  Equipped with a home-grown ERP system, the Company carries a competitive advantage allowing it to forecast staffing needs months in advance and deliver the highest quality work across plumbing systems, HVAC piping and ductwork, process piping and protective jacketing. For additional information, please visit www.thermo-tech.com.

Following the acquisition of Thermo-Tech, IBP’s capabilities stretch across more than 250 locations and over 10,000 employees.  "IBP has long been established as a market leader in residential insulation services,” said Jeffrey Edwards, Chairman and CEO, IBP. "By adding Thermo-Tech and its team to the IBP family of companies,  IBP will be seeking continued growth in the commercial space."

Established in 1977, IBP has grown into one of the largest insulation installers in the United States.  Beyond insulation, IBP installs complementary products including garage doors, gutters and shower doors.  The company is publicly traded on the NYSE (“IBP”). For additional information, please visit www.installedbuildingproducts.com.

About Angle Advisors LLC

Angle Advisors, with offices in the United States, Germany, and China, specializes in mergers and acquisitions (M&A) advisory and capital raising services with a particular emphasis on the industrials and services sectors. The firm’s professionals have completed over 310 transactions since 2009 for multinational corporations, privately held companies, private equity funds, and public sector clients.

Press Inquiries

Kevin Marsh
[email protected]
https://www.angleadvisors.com
101 Southfield Road, 2nd Floor, Birmingham, MI 48009

Key Takeaways Pentair posted Q4 adjusted EPS of $1.18 and sales of $1.02B, beating estimates and rising year over year.PNR saw Flow and Pool sales rise, while Water Solutions sales and earnings declined year over year.Pentair guided 2026 adjusted EPS of $5.25-$5.40, raised its dividend, and kept $1B for share repurchases. Pentair plc (PNR - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.18, which beat the Zacks Consensus Estimate of $1.17. The bottom line also surpassed the company’s guidance of $1.11-$1.16 and improved 9.3% from earnings of $1.08 per share in the prior year.

Including one-time items, EPS was 98 cents compared with the prior-year quarter’s 99 cents.

Net sales improved 4.9% year over year to $1.02 billion. The top line surpassed the Zacks Consensus Estimate of $1.00 billion. Excluding the impacts of acquisitions, divestitures and currency translation, core sales increased 3.7%.

Pentair’s Cost & Margins in Q4The cost of sales increased 2.3% year over year to $609 million. The gross profit was $412 million, up 9.1% from the prior-year quarter. The gross margin was 40.4% compared with the year-ago quarter’s 38.8%.

SG&A expenses totaled $184 million, up 14.7% from the prior-year quarter’s $161 million. Research and development expenses increased 3.2% year over year to $22.5 million.

The operating income was $205 million, up 5.1% from the year-ago quarter. Operating margin was 20.1%, flat year over year.
The adjusted segmental operating income increased 8.8% year over year to $252 million. The adjusted segmental margin was 24.7% compared with the year-ago quarter’s 23.8%.

Pentair’s Q4 Segmental PerformancesNet sales in the Flow segment totaled $394 million, up 9.3% from the prior-year quarter. Our estimate for the segment’s net sales was $387 million. Adjusted operating earnings for the segment rose 22.4% year over year to $90 million. Our estimate for the segment’s operating profit was $80 million.

Net sales in the Water Solutions segment were down 9.9% year over year to $232 million. Our estimate for the segment’s net sales was $244 million. The segment’s earnings were $55 million compared with $62 million in the year-ago quarter. Our estimate was at $63 million.

Net sales in the Pool segment totaled $393 million, up 11.2% year over year. Our estimate for the segment’s net sales was $370 million. Operating earnings for the segment grew 10.7% year over year to $132 million. Our estimate for the segment’s operating income was $121 million.

PNR’s Cash Flow & Balance Sheet UpdatesPentair had cash and cash equivalents of around $102 million at the end of 2025 compared with $119 million at the end of 2024. Net cash generated from operating activities was $815 million in 2025 compared with $767 million in the prior year. The company had a long-term debt of $1.64 billion as of Dec. 31, 2025, flat compared with Dec. 31, 2024.

Pentair hiked its dividend to 27 cents per share from the previous 25 cents. This marks the 50th consecutive year that the company has increased its dividend.

PNR repurchased 0.5 million of its shares for $50 million in the fourth quarter. As of Dec. 31, 2025, the company had $1 billion available under its share repurchase authorization.

PNR’s 2025 PerformancePentair reported an adjusted EPS of $4.92 for 2025, which beat the Zacks Consensus Estimate of $4.91. Earnings were up 13.6% compared with 2024 earnings of $4.33 per share. Pentair had provided an EPS guidance of $4.85-$4.90 for 2025. Including one-time items, EPS was $3.96 compared with the $3.74 in 2024.

Net sales increased 2.3% year over year to $4.18 billion and beat the Zacks Consensus Estimate of $4.16 billion. Excluding the impacts of acquisitions, divestitures and currency translation, core sales were up 1.9%.

Pentair’s Guidance for Q1 & 2026The company expects adjusted EPS of $5.25-$5.40 for 2026. Sales are expected to increase between 3% and 4% on a reported basis from the 2025 level.

For the first quarter, the company expects an adjusted EPS between $1.15 and $1.18. Pentair anticipates the quarter’s sales to increase 1-2% from the year-ago quarter’s figure.

PNR Stock Price PerformancePentair stock has lost 0.4% over the past year compared with the industry’s 3.9% decline.

Image Source: Zacks Investment Research

Pentair’s Zacks RankPentair currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Pentair’s Peers Awaiting ResultsPool Corp. (POOL - Free Report) is slated to release fourth-quarter 2025 results soon. The Zacks Consensus Estimate for POOL’s earnings is pegged at 99 cents per share, indicating year-over-year growth of 2.1%.

The estimate for Pool’s top line is pegged at $998 million, implying an increase of 1.1% from the prior year’s figure. POOL has a trailing four-quarter average earnings surprise of 0.2%.

Xylem Inc. (XYL - Free Report) , scheduled to release fourth-quarter 2025 results on Feb. 10, has a trailing four-quarter average earnings surprise of 8.7%. The Zacks Consensus Estimate for Xylem’s earnings for the quarter is pegged at $1.42 per share, implying year-over-year growth of 20.3%.

The consensus estimate for Xylem’s top line is pegged at $2.38 billion, indicating a rise of 5.4% from the prior-year figure.

Clean Harbors, Inc. (CLH - Free Report) , scheduled to release fourth-quarter 2025 results on Feb. 18, has a trailing four-quarter average earnings surprise of 4.3%. The Zacks Consensus Estimate for Clean Harbors’ earnings for the quarter is pegged at $1.61 per share, implying year-over-year growth of 3.8%.

The consensus estimate for Clean Harbors’ top line is pegged at $1.46 million, indicating a rise of 1.7% from the prior-year figure.

Key Takeaways BMY posted Q4 EPS of $1.26 and revenues of $12.5B, beating estimates and sending the stock higher.BMY's Growth Portfolio revenues rose 16% to $7.39B, driven by immuno-oncology drugs like Opdivo.BMY's Legacy Portfolio fell 15% as generics hit key drugs, while Eliquis sales grew but missed estimates. Bristol-Myers Squibb Company (BMY - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.26, which beat the Zacks Consensus Estimate of $1.15. In the year-ago quarter, BMY posted adjusted earnings per share of $1.67.

Total revenues of $12.5 billion surpassed the Zacks Consensus Estimate of $12.25 billion. Revenues were up 1% from the year-ago period’s level on a reported basis.

The stock is trading up in response to better-than-expected quarterly results.

BMY’s shares have gained 28.5% in the past six months compared with the industry's growth of 43.8%.

Image Source: Zacks Investment Research

Revenues were flat year over year at $8.56 billion in the United States. International revenues increased 5% year over year to $3.94 billion.

Growth Portfolio Powers BMY’s Top Line in Q4BMY’s Growth Portfolio comprises drugs like Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Abecma, Sotyku, Krazati and Cobenfy.

Revenues from the Growth portfolio totaled $7.39 billion, up 16% year over year, driven by the company’s immuno-oncology (IO) portfolio, as well as Reblozyl, Camzyos, and Breyanzi. Sales grew 15% when adjusted for foreign exchange impacts.

Total sales of the immuno-oncology drug Opdivo, approved for multiple cancer indications, increased 9% year over year to $2.69 billion. The figure beat the Zacks Consensus Estimate of $2.60 billion and our model estimate of $2.48 billion. Opdivo Qvantig generated sales of $133 million.

Sales of the rheumatoid arthritis drug Orencia increased 1% to $1.01 billion.

Melanoma drug Yervoy contributed $810 million to the top line. The figure rose 20% year over year. Yervoy sales beat the Zacks Consensus Estimate of $727 million and our model estimate of $692 million.

Reblozyl sales surged 22% year over year to $666 million. Reblozyl sales beat the Zacks Consensus Estimate of $636 million and our model estimate of $641 million.

Opdualag sales jumped 38% to $350 million. The figure beat the Zacks Consensus Estimate of $315 million and our model estimate of $314 million.

Breyanzi sales surged 49% to $392 million and beat the Zacks Consensus Estimate of $380 million and our model estimate of $376 million. Camzyos sales skyrocketed 59% to $353 million.

Sales of Zeposia totaled $160 million, up 1% year over year. Abecma sales declined 4% to $100 million as higher international sales were completely offset by lower U.S. sales.

Sotyktu sales totaled $86 million. Krazati raked in sales of $55 million. The newly approved schizophrenia drug, Cobenfy, generated sales of $51 million.

BMY’s Legacy Portfolio Continues to Decline in Q4Revenues for the Legacy Portfolio decreased 15% to $5.11 billion due to the continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, which offset the increase in Eliquis sales.

Eliquis sales increased 8% year over year to $3.45 billion, driven by growth in U.S. and ex-U.S. sales. The drug is the top revenue generator for BMY. However, sales missed both the Zacks Consensus Estimate of $3.69 billion and our model estimate of $3.59 billion.

Please note that Bristol-Myers has a collaboration agreement with Pfizer (PFE - Free Report) for Eliquis. The companies collaborated in 2007. Profits and losses are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and pays BMY a sales-based fee.

Multiple myeloma (MM) drug Revlimid revenues plummeted 55% to $602 million due to lower demand on account of generic erosion. Sales missed both the Zacks Consensus Estimate of $604 million and our model estimate of $640 million.

MM drug Pomalyst generated sales of $692 million, down 16% year over year.

Leukemia drug Sprycel sales nosedived 60% year over year to $79 million due to generic competition.

Abraxane revenues plunged 52% to $84 million.

Costs and MarginAdjusted gross margin decreased to 71.9% from 74% in the year-ago quarter due to a change in product mix. Adjusted research and development expenses declined 8% to $2.56 billion due to the ongoing strategic productivity initiative. Adjusted marketing, selling and administrative expenses decreased 1% to $2.09 billion due to BMY’s cost-cutting initiative.

BMY recorded acquired IPRD charges of $1.39 billion in the quarter.

BMY’s 2025 ResultsRevenues were relatively flat year over year at $48.19 billion. The figure beat the Zacks Consensus Estimate of $47.95 billion.

The company recorded adjusted EPS of $6.15 in 2025. The figure surpassed the Zacks Consensus Estimate of $6.09.

BMY’s 2026 GuidanceBristol-Myers announced its annual revenue guidance of $46-$47.5 billion for 2026 on the back of the strong performance of the Growth Portfolio.

The Zacks Consensus Estimate for 2026 revenues is pinned at $44.13 billion.

The company expects adjusted earnings to be in the range of $6.05-$6.35 for the full year.

The Zacks Consensus Estimate for 2026 EPS is pegged at $6.08.

BMY’s Key Pipeline UpdatesIn December 2025, the FDA approved Breyanzi as the first and only CAR T treatment for adult patients with relapsed or refractory marginal zone lymphoma who have received at least two prior lines of systemic therapy.

During the quarter, Breyanzi was also approved in the EU for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor.

In late 2025, the FDA accepted a supplemental biologics license application for Opdivo in combination with doxorubicin, vinblastine and dacarbazine for the treatment of adult and pediatric patients (aged 12 years and older) with previously untreated Stage III or IV classical Hodgkin lymphoma, granting the filing priority review status. A regulatory decision is expected by Apr. 8, 2026. A similar application is also currently under review in the EU.

BMY’s Zacks Rank & Stock to ConsiderBristol-Myers currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Alkermes (ALKS - Free Report) and Immunocore (IMCR - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, 2026 EPS estimates for Alkermes have increased from $1.54 to $1.91. Shares of ALKS have gained 28.3% over the past six months.

Alkermes’ earnings beat estimates in three of the trailing four quarters, missing on the remaining occasion, with the average surprise being 4.58%.

Over the past 60 days, estimates for Immunocore’s loss per share for 2026 have narrowed from 97 cents to 90 cents. IMCR stock has lost 3% over the past six months.

Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 53.96%.

Vitalik Buterin, the co-founder of Ethereum (ETH), has withdrawn a sizable portion of his ETH holdings.

Most notably, the entrepreneur has offloaded around 13,220 ETH, worth approximately $33 million, over the last three days with the transactions executed at an average price of about $2,497 per ETH,  according to on-chain data retrieved by Finbold from blockchain analytics platform Arkham on Thursday, February 5.

At press time, Buterin still held $40.28 million worth of cryptocurrency assets, $7 million of which were in Ethereum. As, the Russian-Canadian computer programmer has cut his direct exposure to ETH by roughly 80%.

Vitalik Buterin’s crypto activity. Source: Arkham Intelligence Why is Vitalik selling Ethereum? Large transfers from Buterin’s wallets have attracted market attention, given that ETH has recently lost major daily-chart consolidation zones around $2,800 and $2,700, triggering one of its sharpest sell-offs since mid-2025.

However, the situation might not be as dramatic as it might first seem. Namely, Vitalik had made a statement on X just days before the offloading began, explaining that he intended to reduce a portion of his personal holdings in a period when the ecosystem is facing “mild austerity.”

“In these five years, the Ethereum Foundation is entering a period of mild austerity… For this reason I have just withdrawn 16,384 ETH, which will be deployed toward these goals over the next few years. I am also exploring secure decentralized staking options that will allow even more capital from staking rewards to be put toward these goals in the long term,” the Ethereum co-founder wrote.

In these five years, the Ethereum Foundation is entering a period of mild austerity, in order to be able to simultaneously meet two goals:

1. Deliver on an aggressive roadmap that ensures Ethereum's status as a performant and scalable world computer that does not compromise on…

— vitalik.eth (@VitalikButerin) January 30, 2026 The cut, worth around $45 million, is set aside to support privacy-preserving technologies, open hardware, and secure, verifiable software, with Buterin noting that the funds would be deployed gradually over several years.

Ultimately, then, the heightened wallet activity merely suggests that the philanthropist is executing his plans to build the open and verifiable technology stack that he has promised.

Featured image via Shutterstock

Solana’s dependence on ETF outflows is a double-edged sword: multi-million outflows trash key price thresholds.

Market Sentiment:

Bullish Bearish Neutral

Published: February 5, 2026 │ 3:07 PM GMT

Created by Kornelija Poderskytė from DailyCoin

Solana (SOL) went back below the $100 price range for the first time since 2024, raising eyebrows as ‘extreme fear’ sentiment hits the markets. When large-scale institutions start to trim their digital asset reserves, a mild panic in retail tends to follow.

Solana ETF Hit With $6.7 Million Outflows Below $95This time, Solana’s live exchange-traded funds (ETFs) felt the heat – over $6.7 million were pulled out of all Solana ETFs yesterday, marking the second worst-performing trading day this year. So far, January 30, 2026 was the most turbulent day, marked with $11.24 million in sell-offs.

Cumulatively, all 8 Solana ETFs have pulled in $871 million inflows since the debut trading day. While this figure falls short behind Ripple’s (XRP) $1.21 billion, both of these major-caps saw public recognition from Wall Street & are poised to reap the benefits of regulatory clarity.

Bearish Solana Price Setup Maps Out Next TargetsFrom a technical outlook, Solana (SOL) has established a bearish Head ‘n’ Shoulders pattern. In this case, the head depicts Solana’s cycle tops, while the right should promise a drastic downturn unless the neckline holds. On the monthly Solana price charts, veteran trader Nebraska Gooner highlights the $124 price level as the neck-line.

However, on a weekly basis this neckline area falls to roughly $95, so not restoring this price area would likely push the popular Layer-1 altcoin towards the next major demand territory at $70. In case of a successful $95 neckline reclaim, Solana’s (SOL) price would see the next key obstacle at $115, as it falls within the 0.618 Fibonacci Retracement.

Right now, Solana’s (SOL) price hovers just above $88, dumping 7% on Thursday afternoon after Bitcoin (BTC) briefly fell through the $70,000 support levels. On Futures markets, SOL bears have been dominating like the game is rigged – long SOL price positions accounted for $63.82 million out of $71.25 million in 24-hour liquidations.

The amount of excessively-leveraged plays on Solana’s (SOL) price shows that crypto bulls have miscalculated the rebound chances & didn’t expect the Head ‘n’ Shoulders neckline to break on multiple time-frames. On the other hand, the OI-weighted funding rate flipped back to positive, indicating a time-out in short-selling activities.

On The Flipside Solana’s (SOL) exposure to the ETF markets is arguably larger than XRP’s, accounting for 1.49% of all token supply in comparison to Ripple’s 1.1%. Stay in the loop with DailyCoin’s top crypto scoops:
Shiba Inu Hits Rock Bottom: Price Reversal Or Capitulation?
ZAMA Rebounds Over 19% After Post-Launch Correction

People Also Ask:Where is the neckline on the monthly and weekly charts?

Monthly neckline sits at $124.44—SOL’s already below it, validating the pattern. Weekly neckline at $95—holding here is critical.

Why is SOL tumbling sub-$100 now?

Failed to hold January highs (~$135–$146) amid broader market weakness (BTC dip, ETF sell-offs & general risk-off flows).

What are the bearish implications if the pattern plays out?

Full H&S confirmation targets a measured move down 50–70% from neckline—potentially $40–$60 or lower.

How does this compare to past SOL patterns?

SOL’s seen similar H&S breakdowns in 2022–2023 (post-FTX crash), leading to multi-month lows.

Is there a bullish counter-case?

If $95 holds as support with volume rebound, it could invalidate the pattern and spark a bounce back to $124+ neckline.

DailyCoin's Vibe Check: Which way are you leaning towards after reading this article?

Market Sentiment

100% Bearish

This article is for information purposes only and should not be considered trading or investment advice. Nothing herein shall be construed as financial, legal, or tax advice. Trading forex, cryptocurrencies, and CFDs pose a considerable risk of loss.

TL;DR

Market Decline: BTC has fallen to around $69,300, marking a 21% weekly drop and its first break below $70K since November 2024. Bearish Forecasts: Analysts, including Ali Martinez, Hardy, and PlanB, warn of potential declines toward $57,600, $47,824, or even $30,000, with poll data showing traders expect a move into the $50K to $60K range. Investor Behavior: Rising BTC balances on exchanges suggest traders are preparing to sell, though the RSI near 19 signals oversold conditions that could support a possible rebound.
BTC’s recent downturn has intensified market anxiety, with the asset sliding to levels unseen since late 2024 and analysts warning that deeper losses may be imminent. After falling below $70,000 for the first time in over a year, BTC now trades at around $70,000 again, marking a sharp 21% weekly decline that has rattled bullish sentiment across the sector.

Since 2015, every time Bitcoin $BTC has lost the 100-week SMA, it has failed to reclaim it quickly and instead continued toward the 200-week SMA. https://t.co/ONGc3IV0QN pic.twitter.com/QXbns7q73r

— Ali Charts (@alicharts) February 5, 2026

Analysts Warn of Further Weakness as BTC Tests Key Technical Levels Several market observers argue that the latest correction may only be the beginning. Analyst Ali Martinez highlighted that since 2015, BTC has historically failed to reclaim the 100‑week simple moving average once it breaks below it, often drifting toward the 200‑week SMA. His chart suggests a potential slide to $57,600, with earlier warnings pointing to support at $60,176 and $47,824 after the drop under $77,086.

Some traders foresee an even more dramatic downturn. The analyst known as Hardy projected a prolonged decline that could push BTC toward a $30,000 bottom in the coming months. PlanB also outlined multiple paths, ranging from a collapse to $25,000 to a retreat into the $50,000 to $60,000 zone. In a poll shared on X, nearly half of respondents viewed the $50K to $60K range as the most likely destination, while only 15% anticipated a plunge to $25K. At the time of writing, BTC trades at around $70K, dropping nearly 7%.

Exchange Inflows Rise as Investors Prepare for Possible Sell‑Off On‑chain data appears to support the bearish narrative. CryptoQuant reported a steady increase in Bitcoin held on exchanges in recent weeks, a trend typically associated with investors preparing to sell. The shift from self‑custody to centralized platforms often signals caution, suggesting that many traders expect additional volatility ahead.

Despite the prevailing pessimism, some metrics hint at a potential rebound. The Relative Strength Index, which gauges the speed and magnitude of price movements, currently sits near 19. Readings below 30 indicate oversold conditions, implying that BTC may be nearing a point where buyers could re‑enter the market. While not a guarantee of recovery, the indicator provides a counterbalance to the overwhelmingly bearish sentiment.

Tanzeel Akhtar

Journalist

Tanzeel Akhtar

Part of the Team Since

Feb 2018

About Author

Tanzeel Akhtar has been reporting on cryptocurrency and blockchain technology since 2015. Her work has appeared in leading publications including The Wall Street Journal, Bloomberg, CoinDesk, Bitcoin...

Has Also Written

Last updated: 

35 minutes ago

Tether, issuer of the stablecoin USDT, said it has made a $100 million equity investment in Anchorage Digital, deepening an existing relationship between the two firms.

In a blog post the firm said the investment is being made through Tether Investments and reflects growing focus between stablecoin issuers and federally regulated financial institutions as digital assets continue to integrate into mainstream finance.

Strengthening Regulated Digital Asset InfrastructureAnchorage Digital Bank N.A. is the first federally chartered digital asset bank in the United States, providing institutions with custody, staking, governance, settlement, and stablecoin issuance services.

Tether said the investment reflects its view that Anchorage plays a critical role in enabling digital assets to operate safely and at scale within established regulatory frameworks.

Both firms said they are focused on the foundational infrastructure that supports institutional participation in crypto markets especially as regulatory scrutiny intensifies globally.

Strategic Focus Beyond CapitalTether said its growth has been made by a stronger emphasis on regulatory focus and collaboration with institutions operating under clear legal oversight.

Anchorage Digital’s position at the intersection of regulation and security made it a natural partner as Tether looks to support long-term market integrity.

The relationship between the two companies predates the investment. Anchorage Digital Bank is the issuer of USAT giving Tether direct experience operating within Anchorage’s compliance, custody, and banking framework. That operational familiarity has informed Tether’s decision to take an equity stake.

Institutional Confidence in Stablecoin Infrastructure“Tether exists to challenge the status quo and build global infrastructure for freedom,” said Paolo Ardoino, CEO of Tether. “Our investment in Anchorage Digital reflects a shared belief in the importance of secure, transparent, and resilient financial systems.”

Anchorage Digital CEO and co-founder Nathan McCauley said the investment validates the firm’s long-term approach. “We’ve believed from day one that digital assets would only scale through secure, regulated foundations,” he said.

Positioning for the Next Phase of AdoptionFor Tether the investment reinforces a broader strategy centered on long-term partnerships with regulated institutions that are helping define how stablecoins function within existing financial systems.

As policymakers and institutions continue to shape the future of digital money, infrastructure providers like Anchorage Digital are increasingly seen as critical intermediaries.

Tether and Anchorage Digital said they aim to support broader participation in digital assets while promoting stability, transparency and confidence — pillars they view as essential for the next phase of global digital asset adoption.

Scan QR code to install app

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

Solana’s market looks like a tightly wound spring right now. Prices have been slipping while futures activity is picking up, and that gap is what traders are watching most closely.

It’s a setup that can keep losses rolling — or flip fast if a wave of short covering hits. Either way, the scene is driven more by bets than by steady buying.

Derivatives Betting Intensifies According to reports, more futures contracts for SOL are being opened even as the price moves lower. That means fresh bets are being placed, not just old ones being closed.

Funding rates for perpetual contracts have moved into negative territory. When funding is negative, those backing short positions are paying those on the long side. It’s a clear sign of bearish leaning in the derivatives market.

Leverage A Big Part Of The Story Reports say many of these positions are sized up with leverage. Traders are piling on with borrowed exposure. That raises the odds of violent swings because margin calls can trigger cascades.

A squeeze can happen quickly. If a piece of positive news appears or a large buyer steps in, those who are short may be forced to buy back, and that buying itself can push the price up fast.

Price is going down.
Open Interest is going up.
Funding is going down.$SOL is getting heavily shorted here. pic.twitter.com/YuYAy9lzZ0

— Ted (@TedPillows) February 4, 2026

Price Action Shows Weakness Across short-term charts — intraday and daily — SOL has been under pressure. Spot trading volume remains light, which makes every trade count more.

Some traders are trimming risk because volatility in larger coins has spooked the market. In plain terms: fewer hands are willing to hold SOL at these levels, and that lack of real buying support keeps the downside pathway open.

SOLUSD currently trading at $92,40. Chart: TradingView Volatility Could Swing Either Way This environment is speculative. High open interest plus negative funding is a bearish combo, but it also loads the market with risk.

Covered shorts can unwind in a hurry. Liquidity gaps are where big moves start. The same factors that drive downward momentum can, under different circumstances, accelerate a rebound.

Based on reports, the clearest signals to follow are changes in open interest, shifts in funding rates, and sudden spikes in spot volume or order book depth.

Also watch news flow closely; a single announcement can change sentiment overnight. Risk management matters here. Size positions so that forced liquidations are avoidable.

Featured image from Unsplash, chart from TradingView

Most other altcoins like BNB and XRP have joined the ride south with massive declines of their own.

Bitcoin can’t catch a break in the past several days, marking consecutive multi-month lows, with the latest coming minutes ago at well under $67,000.

The last time the cryptocurrency traded at such low levels was in early November, just as the US presidential elections took place and the country elected the so-called ‘crypto president,’ Donald Trump.

The past few weeks have been brutal for BTC. It challenged $90,000 just eight days ago, last Wednesday, but the rejection at that level brought unimaginable pain for the market leader and most of the altcoin followers.

Bitcoin first dumped to $81,000 last Thursday, then continued south to under $75,000 during the weekend, but the bears kept the pressure on. The past several hours have been violent as well, with BTC plunging to $66,900 (as of press time). This means that the asset has lost well over $20,000 in just over a week.

BTCUSD Feb 5. Source TradingView The altcoins have not been spared. ETH continues with its massive decline, with another 9% daily decline to under $2,000 – its lowest level since last April. BNB has plunged by 10% to $660, while XRP is down by a whopping 15% in the past 24 hours alone to $1.32.

Further losses are evident from the likes of ZEC (-19%), MORPHO (-14%), NEXO (-14%), XMR (-12%), LEO (-12%), SUI (-11%), and many others. As such, it’s no wonder that over-leveraged traders have been harmed severely.

Data from CoinGlass shows that the 24-hour liquidations have rocketed to over $1.3 billion. In the past hour alone, the wrecked positions are up to $350 million. The number of wiped out traders is close to 300,000 daily, with the single-largest position taking place on Aster, which was worth over $11 million.

You may also like: Bitcoin Trading at 41% Discount, Power-Law Model Shows $122K Fair Value Cathie Wood’s Ark Invest Loads Up on Crypto Stocks Amid Market Slump Michael Burry Warns Bitcoin Treasury Firms Face Existential Risk as BTC Slide Deepens Daily Liquidations Data on CoinGlass: February 5 Tags:

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Quick Facts:

➡️ Bhutan’s $22M Bitcoin liquidation highlights the financial pressure on industrial miners due to rising difficulty and costs. ➡️ As L1 spot prices face sell pressure, capital is rotating into infrastructure projects that solve Bitcoin’s scalability limits. ➡️ Bitcoin Hyper uses the Solana Virtual Machine to deliver high-speed, low-cost smart contracts while securing data on Bitcoin L1. ➡️ $HYPER has raised over $31M so far with smart money positioning heavily in the $HYPER presale. Sovereign volatility is back. On-chain data confirms that a wallet linked to the Royal Government of Bhutan, managed by Druk Holding & Investments, recently deposited 367 $BTC to Binance. That movement, valued at approximately $22M, isn’t an isolated event. It’s a symptom of a brutal squeeze in the mining sector.

With Bitcoin’s hash price compressing and operational expenditures (OpEx) for industrial miners climbing, even state-backed entities are liquidating reserves to keep their balance sheets healthy.

The market reaction? Mixed. While a $22M sell wall is absorbable in today’s high-volume environment, the signal is undeniably bearish for short-term Layer 1 price action. It highlights the growing tension between network security costs and miner profitability.

But smart money rarely sits on its hands. As capital rotates out of stagnant spot positions, sophisticated investors are hunting for yield in the emerging Bitcoin Layer 2 ecosystem, a sector designed to solve the scalability issues currently choking the main chain.

This rotation is visible in the flows toward infrastructure projects, unlocking Bitcoin’s dormant capital. Leading the pack is Bitcoin Hyper ($HYPER), a protocol using the Solana Virtual Machine (SVM) to bring high-speed execution to the Bitcoin network.

Bitcoin Hyper ($HYPER) Brings SVM Speeds To The Oldest Blockchain Bitcoin has a utility problem. While it remains the pristine collateral of the crypto world, let’s be honest, it’s sluggish. Transactions crawl, fees spike during congestion, and programmable smart contracts are virtually non-existent on the main chain. Bitcoin Hyper ($HYPER) tackles this by grafting the Solana Virtual Machine (SVM) directly onto the network as a Layer 2 solution.

This architecture allows Bitcoin Hyper to process transactions with Solana-grade speeds while anchoring security to Bitcoin’s Layer 1. For developers, this opens the door to building DeFi apps, NFT platforms, and gaming dApps using Rust, all within the Bitcoin ecosystem.

Bitcoin Hyper uses a decentralized Canonical Bridge to ensure trustless $BTC transfers, effectively turning static Bitcoin into a productive asset.

That matters for adoption. By modifying SPL-compatible tokens for L2 execution, Bitcoin Hyper creates a high-speed payment and DeFi environment that Bitcoin has historically lacked. The protocol operates on a modular framework: Bitcoin L1 handles settlement, while the SVM L2 handles real-time execution.

This separation of concerns allows a single trusted sequencer to manage throughput without compromising the underlying security guarantees of the Bitcoin network.

LEARN MORE ON THE OFFICIAL $HYPER PRESALE PAGE

Whales Accumulate As Smart Money Front-Runs The L2 Narrative While sovereign miners like Bhutan sell to cover costs, a different class of investor is aggressively accumulating early-stage infrastructure. The data surrounding the Bitcoin Hyper presale suggests serious institutional confidence. According to official figures, the project has already raised over $31M.

This liquidity injection isn’t just retail money. Etherscan records show that whales are also in on the action, with one wallet scooping up $500K’s worth of $HYPER. This data point, large singular buys rather than thousands of micro-transactions, indicates that high-net-worth individuals are positioning themselves before the token hits public exchanges.

With the current token price sitting at $0.0136751 and staking rewards at 68%, these entities are securing positions at a valuation that anticipates major future utility. Our experts also predict $HYPER doing well, possibly making it to $0.32 by the end of 2026. If that happens and you’d invested today, it’s an ROI of  2240%

The incentive structure supports the long game, too. Bitcoin Hyper offers high APY staking immediately after the Token Generation Event (TGE). Notably, the protocol enforces a 7-day vesting period for presale stakers. This mechanism (often overlooked by retail flippers) is designed to prevent immediate post-launch dumping, stabilizing the price floor while rewarding those who participate in governance.

For investors watching Bhutan sell L1 assets, rotating into a yield-bearing L2 represents a hedge against mining-induced volatility.

GET YOUR $HYPER ON ITS OFFICIAL PRESALE PAGE

This article is for informational purposes only and does not constitute financial advice. Cryptocurrencies are high-risk assets. The mention of specific dates, such as January 15, 2026, reflects data provided by the project source. Always conduct your own due diligence before investing.

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

TL;DR

ETH broke down on Feb. 3, completing a head-and-shoulders pattern that projects about $1,820 and keeps $1,800 in focus. Lookonchain said Vitalik sold about 2,961.5 ETH worth roughly $6.6 million near $2,228 on average, adding to bearish momentum. Whales reduced holdings by about 140,000 ETH and hodlers showed net selling around 10,681 ETH, while URPD highlights $1,880 as key support; failure could open $1,560, while reclaiming $2,270 and $2,700 matters. Ethereum slid into early February under mounting pressure, and on chain signals now suggest a growing threat of a move toward the $1,800 zone. Price weakness is being amplified by a synchronized pullback from influential and long term holders. A Feb. 5 market note said ETH fell below key support after a chart breakdown confirmed on Feb. 3, while new data showed whales and hodlers beginning to reduce exposure. The update framed $1,800 as the next psychological risk area if support fails.

Technical damage meets high profile selling On the daily chart, ETH completed a head-and-shoulders pattern forming since mid-November, and the bearish reversal was confirmed when price broke the neckline on Feb. 3. The pattern’s measured move targets about $1,820, and Buterin’s selling added fuel to that downside narrative. Lookonchain reported Vitalik sold about 2,961.5 ETH, worth roughly $6.6 million, at an average near $2,228 over three days, with the selling described as ongoing. The note said that timing can weaken confidence and reinforce bearish price action.

After Feb. 3, whales excluding exchange wallets briefly accumulated between Feb. 2 and Feb. 3, then flipped once price failed to rebound. Whales shifted from dip buying to distribution, cutting roughly 140,000 ETH in a rapid risk reset. Holdings fell from about 13.93 million ETH on Feb. 3 to around 13.79 million, a reduction valued at over $290 million. Long-term holders also turned defensive as Hodler Net Position Change moved negative on Feb. 3 and Feb. 4 for the first time in weeks. The latest reading showed net selling around 10,681 ETH, signaling broad conviction is fading.

On-chain cost basis data helps map where support could form, and where a breakdown could intensify. A large supply cluster near $1,880 aligns with the $1,820 projection, creating a make-or-break zone just above $1,800. The URPD model showed one of the strongest clusters near $1,880, with about 2% of circulating ETH last moving there. ETH was described near $2,090 after losing $2,270 support. If $1,880 to $1,820 fails, the next downside target cited was near $1,560. Bearish pressure would ease only if ETH reclaims $2,270, then $2,700, and holds above them on the daily timeframe. Without that recovery, the note said rallies are likely to meet selling pressure and struggle to sustain higher levels for now too.

Thu, 5/02/2026 - 15:42

Bitcoin buyers suffer a brutal four-hour liquidation skew of 2,618% this Thursday, with $118.63 million in longs wiped out as the crypto market enters a violent deleveraging phase many already call apocalyptic.

Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

According to CoinGlass, Bitcoin bulls got steamrolled today — big time. In a ruthless four-hour window, over $118.63 million in long positions were force-liquidated, compared to just $4.53 million in shorts.

That is a 2,618% imbalance — one of the most one-sided liquidation events since 2026.

Source: CoinGlassThe total four-hour “rekt” count hit $123.17 million, exposing a brutal asymmetry in crypto dynamics. This was not just an ordinary liquidation wick. It is fair to call it a direct liquidation flush through long-heavy leverage, mostly concentrated near the $70,000 BTC defense line that had already been under stress since the previous session. 

HOT Stories

Funnily, funding remained elevated across key platforms like Binance and Bybit, suggesting that bulls had not de-risked at all.

What does liquidation imbalance mean for Bitcoin (BTC)?The liquidation imbalance on Feb. 5 points to a leveraged market in denial, holding on to bullish bias while deeper structural breakdowns were already forming across macro, ETF flows and derivatives. 

The 24-hour figures show $466.32 million in long liquidations out of $527.99 million total — over 88% — but the four-hour chart is what caught particular fire.

You Might Also Like

Bitcoin market structure has been cracked during this flush as the leading cryptocurrency hit $69,000, a 2021 all-time high and crucial psychological level for BTC. 

In this case, the 2,618% imbalance is a forensic marker of how far bullish conviction detached from execution risk. 

Should the same environment persist in the next sessions, Bitcoin could be staring at a deeper de-risking cycle that takes it far below current psychological zones, with the $40,000 to $50,000 range acting as a magnet.

Related articles